A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group. The study consists of 2 parts (Part A: monotherapy and Part B: combination therapy with bevacizumab); each part has 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). Enrollment to Part A (Phase 1a and Phase 1b) will include ovarian and endometrial cancers. Enrollment to Part B (Phase 1a and

Trial Details

NCT ID
NCT07470853
Phase
PHASE1
Sponsor
Whitehawk Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • HWK-016, MUCIN-16-targeted ADC
  • Bevacizumab
Locations (sample)
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Los Angeles, California, United States|34.05223,-118.24368
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Peoria, Illinois, United States|40.69365,-89.58899
  • Detroit, Michigan, United States|42.33143,-83.04575

Key Eligibility Criteria

  • Have one of the following solid tumor cancers:
  • Monotherapy escalation, backfill and expansion cohorts:
  • Endometrial Carcinoma
  • Ovarian Cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →